Novo Nordisk Slashes List Prices for Weight-Loss and Diabetes Drugs by Up to 50 Percent
Novo Nordisk announced Tuesday that it will slash list prices for three of its most popular drugs by up to 50 percent beginning January 1, 2027. Ozempic, Wegovy, and Rybelsus will all cost $675 per month across the board in the United States. For patients currently paying full list price, the new $675 monthly cost represents a reduction in what they owe at the pharmacy counter each time they refill their prescriptions.
The price cut applies to Novo Nordisk's semaglutide products, the class of medications that have become household names over the past two years. Ozempic treats type 2 diabetes. Wegovy is prescribed for weight loss. Rybelsus is an oral form of semaglutide for diabetes. Together, these three drugs have generated billions in revenue for the Danish pharmaceutical company, making them among the most profitable medications on the market.
What This Means for Your Wallet
For uninsured patients and those paying out-of-pocket, the new pricing will reduce monthly costs. The extent of savings will depend on patients' current out-of-pocket costs and insurance coverage.
Insured patients are unlikely to see direct copay changes, since insurers negotiate separate rebates and discounts unrelated to list price. Insurance copay structures vary by plan and are set by insurers, not pharmaceutical companies.
Why Now
The announcement follows years of public pressure over high launch prices and growing competition from rival GLP-1 drugs. Patient advocacy groups and policymakers have called for lower prices on these medications. Novo Nordisk has not publicly stated its rationale for the price reduction.
When the Savings Begin
The new prices take effect on January 1, 2027, giving patients and insurers 11 months to prepare for the change. Patients currently taking any of these three medications should not expect immediate savings, as the reduction won't apply until January 1, 2027.
